IL-33 reduces macrophage foam cell formation.

Area of Science:

• Immunology
• Cardiovascular Biology
• Cell Biology

Background:

• Atherosclerosis is a chronic inflammatory disease involving arterial fibrotic plaques.
• Macrophage foam cell formation is a critical feature of atherosclerotic plaques.
• The direct effect of Interleukin-33 (IL-33) on macrophage foam cell formation is not well understood.

Purpose of the Study:

• To investigate the role of IL-33 in reducing macrophage foam cell accumulation in vivo.
• To determine if IL-33 directly inhibits macrophage foam cell formation in vitro.
• To elucidate the molecular mechanisms underlying IL-33's action on macrophage cholesterol metabolism.

Main Methods:

• Apolipoprotein E knockout mice on a high-fat diet were used to study IL-33 effects in vivo.
• THP-1 cells and primary human monocyte-derived macrophages were used for in vitro studies.
• Gene expression analysis, cholesterol uptake, and efflux assays were performed.

Main Results:

• IL-33 treatment significantly reduced macrophage foam cell accumulation in atherosclerotic plaques in vivo.
• In vitro, IL-33 decreased modified low-density lipoprotein uptake and intracellular cholesterol, while enhancing cholesterol efflux.
• IL-33 modulated the expression of genes involved in lipoprotein uptake (e.g., CD36), cholesterol efflux (e.g., Apolipoprotein E), and cholesterol esterification.

Conclusions:

• IL-33 plays a protective role in atherosclerosis by inhibiting macrophage foam cell formation.
• The IL-33 receptor, ST2, is essential for IL-33's effects on macrophage foam cell formation.
• IL-33 represents a potential therapeutic target for atherosclerosis treatment.